Oragenics, Inc. Announces Management Changes and Shareholder ApprovalsSarasota, FL – December 11, 2024 – Oragenics, Inc. (NYSE: OGEN) recently filed a Form 8-K with the Securities and Exchange Commission, revealing significant developments within the

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Oragenics’s 8K filing here.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.